Last reviewed · How we verify
Neratinib tablets
At a glance
| Generic name | Neratinib tablets |
|---|---|
| Also known as | Epilepsy, Neratinib |
| Sponsor | Convalife (Shanghai) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer (PHASE2)
- Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor (PHASE2)
- Neratinib in Combination With Ruxolitinib in Patients With mTNBC (EARLY_PHASE1)
- INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) (PHASE2)
- Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study
- Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test (PHASE1, PHASE2)
- Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib (PHASE2)
- Using Tumor Models to Determine Treatments (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neratinib tablets CI brief — competitive landscape report
- Neratinib tablets updates RSS · CI watch RSS
- Convalife (Shanghai) Co., Ltd. portfolio CI